[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fatty-liver\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fatty-liver":641},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,49,81,103,121,152,174,201,228,256,278,293,322,354,390,426,447,469,496,517,541,563,581,600,616],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100322739",false,"NCT03481829","Early Tracking of Childhood Health Determinants (ETCHED) Study","Early Tracking of Childhood Health Determinants Study","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Pregnant women aged 18 years or older (pregnancy confirmed by urine or serum pregnancy test, or ultrasound examination)\n2. American Indian or Hispanic by self-report\n3. Agree to continue with research study participation (both mother and their offspring), for at least 3 years after delivery.\n\nIn case where a pregnant mother is carrying multiple fetuses (multiple pregnancy), she will be eligible to participate in this study and all her live newborns, as a result of that pregnancy, will be eligible for participation in this study. Mothers will also be eligible to participate with any consecutive pregnancies.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Women who are incarcerated or are unable to consent.\n2. Women whose fetus is not viable or are not planning to continue the pregnancy.",true,"ALL","1 Day","99 Years",{"count":21,"type":22},1500,"ESTIMATED","OBSERVATIONAL","Background:\n\nChildren s weight has increased sharply in recent years. This may put them at higher risk for health problems. High blood glucose in a pregnant mother and too much weight gain during pregnancy also may have long-term effects on the child s health. Children who become overweight or obese during childhood tend to remain so as adults. Researchers want to study many risk factors during and after pregnancy, and how these affect a child s development. They will also follow the mother s health and well-being after pregnancy.\n\nObjectives:\n\nTo learn how a pregnant mother s environment, lifestyle, and health conditions may affect her child s growth and development from birth until adulthood.\n\nEligibility:\n\nAmerican Indian\u002FAlaska Native (AI\u002FAN) or Hispanic adult pregnant women and their offspring.\n\nDesign:\n\nMothers will have 3 visits during pregnancy.\n\nIn the child s first year, mothers will have 2 visits and their child will have 4.\n\nChildren will have 2 visits in their second year and 1 each year until they turn 18.\n\nMothers will have a visit 2 years after birth and 4-5 years later.\n\nBoth the mother and child s medical records will be reviewed. They will have physical exams and give blood and stool samples.\n\nMothers may give cord blood and placenta samples. They will give breastmilk and urine samples. They will fill out questionnaires.\n\nThey will have an ultrasound. They may get an activity monitor.\n\nMother and child will be followed until the child s 18th birthday.\n\n...",[26,27,28],"Diabetes Mellitus","Obesity","Fatty Liver",[30,27,31,32,33,34,35],"American Indians, Hispanics","Pregnancy","Diabetes","Children","Hispanics","Natural History","RECRUITING","2026-06-27",{"date":39,"type":40},"2026-06-30","ACTUAL",{"date":42,"type":40},"2022-04-14",{"date":44,"type":22},"2041-12-31",{"name":46,"class":47},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",1,{"id":50,"slug":4,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":76,"leadSponsor":78,"locationsCount":48},"100643233","NCT07646197","Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease","Impacts of Peanut Intake on Hepatic Markers and Gut Microbiota in Adults With MASLD","Inclusion Criteria:\n\n* 30-70 years\n* do not consume peanut\u002Fpeanut butter\u002Ftreenut\u002Fseeds \\> \u002Fweek\n* at least one encounter-related (stage F0\u002FF1) MASLD diagnosis (K76.0)\n* Able to understand, speak, and read English\n* Mentally competent to consent\n\nExclusion Criteria:\n\n* Food allergy to peanuts or peanut-containing products\n* With alcohol use disorder (AUDIT screening)\n* Leukemia\n* Lymphoma\n* Other types of cancer\n* Heart or cardiovascular diseases (such as heart attack, stroke, heart failure)\n* Kidney diseases (such as chronic kidney disease, kidney transplant, renal insufficiency such as renal failure requiring dialysis)","30 Years","70 Years",{"count":58,"type":22},125,"INTERVENTIONAL",[61],"NA","The aim of this randomized interventional trial is to understand the effects of peanut consumption on patients with metabolic associated fatty liver. The main goal is to investigate if patients who consume peanuts have improved liver marker tests as well as metabolic profile. We will also investigate how peanuts alter the gut microbes and liver fat content in patients with metabolic associated fatty liver.\n\n* Participants will be randomized into intervention (peanut consumption for 12 weeks) and control (regular diet) arm.\n* Stool sample and blood (for biomarkers) collection across both arms at baseline and post-intervention\n* Daily log to be completed for tracking peanut consumption\n* 2-day Dietary recall at baseline, during Week 6 and Week 12\n* Poat intervention Fibro scans for participants with baseline scans available",[64,28],"MASLD",[66,67,68,69,70,71],"fatty liver","masld","peanut","hepatic","intervention","gut microbe","2026-06-09",{"date":74,"type":40},"2026-06-12",{"date":72,"type":22},{"date":77,"type":22},"2028-06-09",{"name":79,"class":80},"Henry Ford Health System","OTHER",{"id":82,"slug":4,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":64,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":48},"100642794","NCT07636915","Association Between Fatty Liver and Inflammatory Biomarkers","Association Between Systemic Inflammatory Indexes and Metabolic Dysfunction Associated Steatotic Liver Disease","Inclusion Criteria:\n\n* Patient older than 18 years were diagnosed with MASLD according to Delphi consensus criteria (Rinella et al., 2024). Attend to outpatient clinic of Tropical Medicine Department, Sohag University\n\nExclusion Criteria:\n\n1. Significant alcohol consumption (\\>20 g\u002Fday for females, \\>30 g\u002Fday for males).\n2. Other causes of chronic liver disease:\n\n   * Viral hepatitis (HBV, HCV)\n   * Autoimmune hepatitis.\n   * Wilson's disease.\n   * Hemochromatosis.\n   * Drug-induced liver injury.\n3. Active infection or acute inflammatory conditions.\n4. Malignancy.\n5. Pregnancy.","18 Years",{"count":89,"type":22},100,"The newly adapted definition for MASLD includes evidence for hepatic steatosis by imaging or biopsy with at least one of the five cardiometabolic criteria; BMI ≥ 25 kg\u002Fm2 (≥23 kg\u002Fm2 in Asian) or waist circumference \\>94 cm in men, \\>80 cm in women, fasting serum glucose ≥ 126 mg\u002FdL or 2 hour post load glucose level ≥ 140 mg\u002FdL or HbA1c ≥ 5.7% or on treatment for type 2 diabetes mellitus ,blood pressure ≥130\u002F85 mmHg or antihypertensive treatment, plasma triglycerides ≥ 150 mg\u002FdL or on lipid lowering drug, and plasma HDL cholesterol \\\u003C 40 mg\u002FdL for men and \\\u003C 50 mg\u002FdL for women or on lipid lowering drug treatment (Rinella et al., 2024).\n\nThese metabolic factors contribute to disease progression from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), advanced fibrosis, cirrhosis, and hepatocellular carcinoma (Eid et al., 2024).\n\nWhile multiple biological pathways contribute to MASLD pathogenesis; systemic inflammation has emerged as a pivotal mechanism linking metabolic dysfunction to liver injury (Bessone et al., 2019)",[28],[64],"NOT_YET_RECRUITING","2026-06-08",{"date":96,"type":40},"2026-06-10",{"date":98,"type":22},"2026-07-01",{"date":100,"type":22},"2027-03-01",{"name":102,"class":80},"Sohag University",{"id":104,"slug":4,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":48},"100533390","NCT06225193","Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population","Inclusion Criteria:\n\n* Age: ≥ 18 years\n* NAFLD\u002FNASH and non-NAFLD\u002FNASH patients who have had an assessment with ELF score at Methodist Dallas Medical Center from November 2021 to December 2023.\n\nExclusion Criteria:\n\n* Patients with incomplete data and those lost to follow up.",{"count":109,"type":22},300,"In this initial investigator-initiated retrospective study, aim to analyze the enhanced liver fibrosis (ELF) scores in this high-risk population for NAFLD\u002Fnonalcoholic steatohepatitis(NASH)-related fibrosis. Study define 'high-risk' to include metabolic syndrome, which can be further defined by an atherosclerotic cardiovascular disease (ASCVD) score \\>7.5, any diagnosis of hyperlipidemia, history of coronary artery disease, history of heart failure, hypertension and\u002For type 2 diabetes. Study would also like to compare the performance of this score with historical methods of fibrosis assessment, where applicable, including vibration-controlled transient elastography, magnetic resonance elastography, blood markers and liver biopsy. Study will assess the impact of ELF scores on predicting liver events in the time, have used it and determine if diet, lifestyle changes and\u002For pharmacotherapy will improve serial ELF scores. Will also seek to understand how ELF scores are distributed in our community.",[28],"2026-05-11",{"date":114,"type":40},"2026-05-13",{"date":116,"type":40},"2023-06-20",{"date":118,"type":22},"2026-06-23",{"name":120,"class":80},"Methodist Health System",{"id":122,"slug":4,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":16,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":128,"targetDuration":130,"studyType":23,"phases":4,"briefSummary":131,"conditions":132,"keywords":135,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":48},"100633725","NCT07530419","Samsung S-Viscosity vs Canon Dispersion Slope in Steatotic Liver Disease (SAVID-SLD)","Prospective Evaluation of Samsung Medison 2D Shear Wave Elastography Viscoelasticity Parameters in Patients With Steatotic Liver Disease Using Canon Dispersion Slope Imaging as Reference Standard: A Single-Center Non-Interventional Observational Study","SAVID-SLD","Inclusion Criteria:\n\n* \\[Cohort A - Healthy reference\\]\n\n  * Adults ≥18 years old\n  * Currently undergoing living-donor evaluation at SNUH\n  * Donor evaluation confirms (a) hepatic steatosis \\\u003C5% by imaging or biopsy, (b) normal AST\u002FALT, and (c) absence of chronic liver disease (HBV, HCV, autoimmune, cholestatic, etc.)\n  * Provided written informed consent \\[Cohort B + C - Steatotic liver disease\\]\n  * Adults ≥18 years old\n  * Sonographically suspected or confirmed hepatic steatosis on B-mode ultrasound, scheduled for clinical abdominal ultrasound\n  * Serum AST\u002FALT results available within 6 weeks of ultrasound, or scheduled\n  * Provided written informed consent\n\nExclusion Criteria:\n\n* • Significant alcohol intake within the past 2 years (\\>30-60 g\u002Fday for males, \\>20-50 g\u002Fday for females)\n\n  * Diagnosed or strongly suspected chronic liver disease (active HBV\u002FHCV, autoimmune liver disease, cholestatic liver disease, Wilson's disease, hemochromatosis, etc.)\n  * Suspected hepatic failure or decompensated cirrhosis (albumin \\\u003C3.2 g\u002FdL, INR \\>1.3, direct bilirubin \\>1.3 mg\u002FdL)\n  * Ascites, history of variceal bleeding, or acute biliary obstruction rendering stable measurements unfeasible\n  * History of liver malignancy or treatment for liver malignancy\n  * History of liver surgery\n  * Pregnancy or lactation\n  * Inadequate ultrasound image quality due to obesity, bowel gas, or patient inability to cooperate",{"count":129,"type":22},95,"1 Week","Steatotic liver disease (SLD) is one of the most common chronic liver diseases worldwide. Distinguishing simple steatosis from metabolic dysfunction-associated steatohepatitis (MASH) with significant fibrosis is clinically important, but liver biopsy - the current standard - is invasive. Recent ultrasound technology allows noninvasive measurement of tissue viscoelasticity, which has been linked to liver inflammation. Samsung Medison's HERA W12 system (S-Viscosity) and Canon Aplio i800 (Dispersion Slope Imaging) both provide vendor-specific viscoelasticity parameters derived from shear-wave dispersion analysis, but their relationship and agreement have not been compared in SLD patients.\n\nThis prospective single-center observational study will enroll approximately 95-100 participants in three cohorts: (A) 15-20 living-donor candidates as a healthy reference, (B+C) approximately 80 adults with sonographically suspected or confirmed SLD recruited consecutively. SLD participants will be classified post-hoc into low-MASH-risk (Cohort B) and at-risk MASH (Cohort C) subgroups using a multi-parametric stratification combining liver stiffness (LSM), DeepUSFF (deep-learning-based ultrasound fat fraction), and serum AST. All participants will undergo same-day ultrasound examination with both Samsung HERA W12 and Canon Aplio i800. The primary objective is to evaluate the correlation and agreement between Samsung S-Viscosity and Canon Dispersion Slope. Secondary objectives include deriving a normal reference range from the healthy cohort, comparing viscoelasticity parameters across cohorts, and exploring a Modified US-FAST score.",[133,28,134],"Metabolic Dysfunction-Associated Steatotic Liver Disease","Liver Fibrosis",[136,137,138,139,140,64,141,142],"Shear wave elastography","Viscoelasticity","Dispersion slope","Liver stiffness","Quantitative ultrasound","MASH","S-Viscosity","2026-04-08",{"date":145,"type":40},"2026-04-15",{"date":147,"type":22},"2026-04-10",{"date":149,"type":22},"2027-02-28",{"name":151,"class":80},"Seoul National University Hospital",{"id":153,"slug":4,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":59,"phases":159,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":48},"100631027","NCT07495332","Siemens Biomarker Multi-modality","Inclusion Criteria:\n\n* Age of 18 years or older\n* Has clinically indicated CT schedule including the liver (with contrast or with and without contrast)\n* Patient eligible for MR imaging\n* History of chronic diffuse liver disease, steatotic liver disease, and\u002F or liver fibrosis\n* Capable of consent\n\nExclusion Criteria:\n\n* Contraindications to any of the required imaging examinations\n* BMI \\> 45 (based on MRI scanner capacity)",{"count":158,"type":22},45,[61],"The purpose of this study is to see how well Photon Counting CT (PCCT) and ultrasound test results can find fat and scarring in the liver. They will be compared to MRI test results as the reference standard. Participants will get a regular CT scan on the PCCT scanner, plus a few extra pictures just for the study. They will also get an MRI, either on the same day or a different day, whichever is preferred. Participants will get an ultrasound on the same day as the MRI. If they have not had a hematocrit blood test in the past 24 hours, they will also receive one on the day of the CT scan.",[28,162],"Hepatic Steatosis",[28,134,164],"Hepatic steatosis","2026-04-02",{"date":167,"type":40},"2026-04-03",{"date":169,"type":40},"2026-03-27",{"date":171,"type":22},"2027-05",{"name":173,"class":80},"Duke University",{"id":175,"slug":4,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":59,"phases":184,"briefSummary":185,"conditions":186,"keywords":189,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":48},"100558074","NCT06546384","GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease","Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease","GLP-1 RA","Inclusion Criteria:\n\n* BMI ≥ 35 kg\u002Fm² OR BMI ≥ 28 kg\u002Fm² in the case of weight-related co-morbidities (pre-diabetes or type 2 diabetes mellitus, hypertension, dyslipidemia).\n* Fatty liver disease (steatosis on ultrasound and\u002For CAP value on FS \\> 238 dB\u002Fm)\n* Age 18 - 80 years\n* Alcohol Use Disorder Identification Test-C Score \\>4 (AUDIT-C) Score ≥4 for women and ≥5 for men (as measured from AUDIT-questionnaire distributed in visit 1)\n* Sufficient skills for German or French language (written and spoken)\n* Signed informed consent\n\nExclusion Criteria:\n\n* Active illicit substance use\n* AUDIT-score \\\u003C 5 (males)\u002F 4 (females) (as measured from AUDIT-questionnaire distributed in visit 1)\n* Current treatment with drugs against alcohol dependence (disulfiram, acamprosate, naltrexone, baclofen and nalmefene)\n* Any known contraindication to semaglutide\n* Presence or history of a hepatic or extrahepatic malignancy from the previous 6 months","80 Years",{"count":183,"type":22},64,[61],"There is evidence that alcoholic beverage consumption significantly interacts with food energy intake. Furthermore, there is accumulating evidence showing independent, combined, and modifying effects of alcohol and metabolic factors on the onset and progression of chronic liver disease. Preclinical and clinical data have showed that GLP-1 RA can decrease alcohol consumption, particularly in obese patients. Moreover there is evidence that semaglutide can improve the liver sinusoidal milieu in pre-clinical models of cirrhosis.\n\nIn this study, the investigators aim to assess if patients treated with semaglutide and receiving counselling will achieve a significantly higher alcohol abstinence compared to patients only receiving counselling.",[187,28,188],"Adiposity","Alcohol Use Disorder",[190,191],"GLP-1","Semaglutide","2026-02-23",{"date":194,"type":40},"2026-02-25",{"date":196,"type":22},"2026-05-01",{"date":198,"type":22},"2027-04-30",{"name":200,"class":80},"Insel Gruppe AG, University Hospital Bern",{"id":202,"slug":4,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":59,"phases":211,"briefSummary":212,"conditions":213,"keywords":216,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":48},"100623666","NCT07399600","Personalized Transcranial Magnetic Stimulation (TMS) for Metabolic Dysfunction and Alcohol-Related Liver Disease","Personalized Transcranial Magnetic Stimulation for Metabolic Dysfunction and Alcohol-Related Liver Disease (MetALD): A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial","P-TMS MetALD","Inclusion Criteria:\n\n* Participants are able to understand the study protocol, requirements, and restrictions, are fully informed of potential adverse events, are willing to comply with follow-up visits, and voluntarily sign the informed consent form before enrollment.\n* Meet the diagnostic criteria for MASLD according to the Guidelines for the Prevention and Treatment of Metabolic (Non-Alcoholic) Fatty Liver Disease (2024 Edition), and fulfill the European definition of MetALD with moderate alcohol consumption (20-50 g\u002Fday for women; 30-60 g\u002Fday for men).\n* Age between 18 and 65 years.\n* Body mass index (BMI) \\> 24 kg\u002Fm².\n* No history of alcohol abuse.\n\nExclusion Criteria:\n\n* Contraindications to magnetic resonance imaging (MRI) or transcranial magnetic stimulation (TMS).\n* Mild cognitive impairment, defined as Montreal Cognitive Assessment (MoCA) score \\\u003C 25.\n* Severe comorbid somatic diseases or neurological disorders.\n* History of psychiatric disorders, or current use of antipsychotic medications.\n* Pregnant or breastfeeding women, or those planning pregnancy.\n* Previous TMS treatment within the last 3 months.","65 Years",{"count":210,"type":22},105,[61],"The goal of this clinical trial is to learn if repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive brain stimulation technique, works to treat Metabolic dysfunction-associated and alcohol-associated liver disease (MetALD). The main questions it aims to answer are:\n\n* Can rTMS effectively treat MetALD?\n* Is an individualized, precision-targeted rTMS approach more effective than the standard rTMS method?\n* What changes in brain activity are associated with the treatment?\n\nResearchers will compare three different types of stimulation:\n\n* Group A: Individualized rTMS targeting a deep brain reward area (the Nucleus Accumbens) based on each participant's brain scan (fMRI).\n* Group B: Standard rTMS applied using the traditional \"5 cm\" rule for positioning.\n* Group C: Sham (placebo) rTMS, which mimics the procedure but delivers no significant magnetic stimulation.\n\nParticipants will:\n\n* Be randomly assigned to one of the three groups (A, B, or C).\n* Undergo an MRI brain scan before starting treatment.\n* Receive a total of 20 rTMS sessions, completing at least 4 sessions per week.\n* Have additional MRI scans and clinical assessments halfway through and immediately after the treatment course.\n* Attend follow-up visits at 1, 3, and 6 months after treatment completion to assess long-term effects.",[214,28,215],"Liver Diseases, Alcoholic","Metabolic Syndrome",[214,28,215,217,218],"Transcranial Magnetic Stimulation","Randomized Controlled Trial","2026-02-03",{"date":221,"type":40},"2026-02-10",{"date":223,"type":22},"2026-02-01",{"date":225,"type":22},"2027-12-31",{"name":227,"class":80},"The Affiliated Hospital of Hangzhou Normal University",{"id":229,"slug":4,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":59,"phases":235,"briefSummary":236,"conditions":237,"keywords":242,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":48},"100431516","NCT04899102","Intermittent Fasting for NAFLD in Adults","Pilot Study of Time-Restricted, Intermittent Fasting for Non-Alcoholic Fatty Liver Disease in Non-Obese Adults","Inclusion Criteria:\n\n1. Willing and able to provide informed consent\n2. Age 18 years or older at time of consent\n3. BMI 23-30kg\u002Fm\\^2 at screening\n4. Evidence of NAFLD confirmed by historical procedure obtained no more than 6 months prior to the screening visit, defined as:\n\n   * Grade \\>=1 steatosis on clinical liver biopsy; OR\n   * Fatty liver on validated imaging modality (non-contrast CT scan, MR Spectroscopy, MRI proton density fat fraction, ultrasound)\n5. Liver fat fraction ≥10% on H-MRS performed during the screening period\n6. Hepatitis C antibody and Hepatitis B surface antigen negative at screening\n\nExclusion Criteria:\n\n1. Heavy alcohol use for at least 3 consecutive months within the past 5 years prior to screening \\[heavy alcohol consumption is defined as: \\> 20g daily for women or \\> 30mg daily for men, assessed by the Lifetime Drinking History assessment at screening (23, 24)\\].\n2. Evidence of other known forms of chronic liver disease including:\n\n   • Alcoholic liver disease, hepatitis B, hepatitis C, PBC, PSC, autoimmune hepatitis, Wilson disease, iron overload, alpha-1-antitrypsin deficiency, drug-induced liver injury, known or suspected hepatocellular carcinoma (HCC).\n3. Current or prior history of Type II Diabetes requiring insulin or sulfonylureas due to risk of hypoglycemia with fasting.\n4. Use of any pharmacological treatments for NAFLD\u002FNASH within the 6 months prior to the screening visit, except vitamin E. Patients on a stable dose of vitamin E can be enrolled in the study.\n5. Unstable body weight \\[defined as: \\>10% reduction in body weight in the 6 months prior to the screening visit\\]\n6. Known cirrhosis, stage 4 fibrosis on prior liver biopsy, or clinical evidence of cirrhosis or portal hypertension on imaging or exam.\n7. Current or prior history of Child-Pugh score ≥7.\n8. History of liver transplant, or current placement on a liver transplant list.\n9. Known positivity for human immunodeficiency virus infection.\n10. Prior or planned bariatric surgery, patients on active pharmacological treatment for weight loss, or active involvement in a weight loss program.\n11. Routine MRI exclusion criteria, such as the presence of a pacemaker or cerebral aneurysm clip.\n12. Chronic Kidney Disease (CKD) with eGFR \\\u003C 60.\n13. For women of child-bearing potential (WOCBP): positive urine hCG, trying to achieve pregnancy, or breastfeeding \\[a negative urine pregnancy test is required at screening for women of child-bearing potential\\].\n14. Other medical conditions or severe chronic illnesses that, in the opinion of the Investigator, may present a contraindication to study participation.\n15. Any other condition that, in the opinion of the Investigator, may hinder study compliance or completion of the study schedule of assessments.",{"count":7,"type":22},[61],"NAFLD is a growing threat to public health. Currently, there is a significant need for highly effective treatments for NAFLD. Non-obese NAFLD (BMI\\\u003C30kg\u002Fm2) is an increasingly recognized condition, sometimes described as \"lean NAFLD\". Intermittent Fasting (IF) may be uniquely beneficial in non-obese NAFLD. The purpose of this study is to identify non-pharmacologic, lifestyle-based methods of NAFLD treatment within non-obese adults.",[28,238,239,240,241],"Intermittent Fasting","Fatty Liver, Nonalcoholic","Non-Alcoholic Fatty Liver Disease","Liver Fat",[28,238,243,244,245,246,241,240,239],"Non-obese","Diet","Nutrition","Time-restricted","2025-12-10",{"date":249,"type":40},"2025-12-18",{"date":251,"type":40},"2022-02-01",{"date":253,"type":22},"2026-07-31",{"name":255,"class":80},"Massachusetts General Hospital",{"id":257,"slug":4,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":262,"enrollmentInfo":263,"targetDuration":4,"studyType":59,"phases":265,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":48},"100611564","NCT07242222","Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease","Evaluating the Safety and Efficacy of Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients","Inclusion Criteria:\n\nEither male or female adult patients (\\>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography (US).\n\nExclusion Criteria:\n\nPregnant and\u002For lactating women, excessive alcohol use (defined as an average alcohol intake \\> 30 g per day in men and \\> 20 g per day in women).\n\nOther etiology of chronic liver diseases such as viral hepatitis, drug-induced hepatitis, and autoimmune hepatitis.\n\nPatients suffering from chronic kidney disease, hyper\u002Fhypoparathyroidism. Hypersensitivity to erdostiene.","60 Years",{"count":264,"type":22},50,[266,267],"PHASE1","PHASE2","Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries (1). NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. NAFLD is characterized by excessive hepatic fat accumulation without other recognized causes of increased fat content (e.g., alcohol, virus, drugs, and autoimmunity). According to the Clinical Practice Guidelines of the European Association for the Study of the Liver, the diagnosis of NAFLD requires the exclusion of daily alcohol consumption \\>30 g for men and \\>20 g for women",[28],"2025-12-03",{"date":247,"type":40},{"date":273,"type":40},"2025-11-20",{"date":275,"type":22},"2026-11-20",{"name":277,"class":80},"Tanta University",{"id":279,"slug":4,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":262,"enrollmentInfo":284,"targetDuration":4,"studyType":59,"phases":285,"briefSummary":268,"conditions":286,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":292,"locationsCount":48},"100611315","NCT07238985","Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease","Evaluating the Safety and Efficacy of Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease Patients.","Inclusion Criteria:\n\nEither male or female adult patients (\\>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography (US).\n\nExclusion Criteria:\n\nPregnant and\u002For lactating women, excessive alcohol use (defined as an average alcohol intake \\> 30 g per day in men and \\> 20 g per day in women).\n\nOther etiology of chronic liver diseases such as viral hepatitis, drug-induced hepatitis, autoimmune hepatitis.\n\nPatients suffering from chronic kidney disease, hyper\u002Fhypoparathyroidism, and congestive heart failure patients",{"count":264,"type":22},[266,267],[28],{"date":288,"type":40},"2025-11-25",{"date":290,"type":40},"2025-11-01",{"date":275,"type":22},{"name":277,"class":80},{"id":294,"slug":4,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":300,"enrollmentInfo":301,"targetDuration":4,"studyType":59,"phases":303,"briefSummary":304,"conditions":305,"keywords":310,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":48},"100562188","NCT06599918","Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)","Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Nicotinamide in Patients With and Liver Fibrosis (NICOFIB)","NICOFIB","Inclusion Criteria:\n\n* Patients aged between 18 and 85 years.\n* Diagnosis of non-alcoholic fatty liver disease (NAFLD) by their referring physicians (NAFLD defined as the presence of hepatic steatosis and in the absence of significant alcohol consumption, having excluded other liver diseases).\n* BMI between 27-40 kg\u002Fm2.\n* Fibroscan® value greater than 9.2 kPa, obtained within the last 6 months prior to the start of the study.\n\nExclusion Criteria:\n\n* Patients with any medical condition or illness that, in the opinion of the investigator, could interfere with the study results and\u002For affect the patients' ability to participate or complete the study.\n* History of clinically significant heart disease (ejection fraction \\\u003C40% \\[normal range 50-70%\\], heart failure defined as New York Heart Association \\[NYHA\\] Class \\> 2; clinically significant congenital or acquired valvular disease; symptomatic coronary artery disease such as myocardial infarction or angina, history of unstable arrhythmias, history of atrial fibrillation).\n* Decreased renal function (estimated glomerular filtration rate \\\u003C45 mL\u002Fmin\u002F1.73 m2, calculated using the CKD-EPI formula) at screening.\n* Alcohol consumption exceeding 30 g\u002Fday in men or 20 g\u002Fday in women.\n* Patients with significant impairment of liver function in the selection analysis defined as repeated values of AST, ALT, and bilirubin \\> 3 times the upper limit of normal.\n* Positive for hepatitis B surface antigen or hepatitis C antibodies.\n* Patients with hepatocellular carcinoma.\n* Patients with liver cirrhosis (Fibroscan® \\> 18, compatible biopsy, or those who have experienced decompensations of cirrhosis).\n* Patients diagnosed with human immunodeficiency virus (HIV).\n* Patients with hypersensitivity or a history of severe allergies to NAM or excipients used in the preparation of capsules (NAM and placebo).\n* Patients with iodinated contrast allergy.\n* History or evidence of an autoimmune disorder considered clinically significant by the investigator or requiring systemic, chronic use of systemic corticosteroids or other immunosuppressants.\n* Patients on treatment with hepatotoxic drugs (amiodarone, immunosuppressants, ART, antituberculosis drugs, corticosteroids, etc.).\n* Patients consuming narcotic and psychotropic substances with hepatotoxic effects.\n* Individuals with incapacitating diseases or cognitive impairment.\n* Institutionalized patients or those without a fixed address.\n* Principal investigator's discretion in case of indications of low adherence to the trial or follow-up visits.\n* Individuals with a life expectancy of less than 12 months.\n* Patients participating in another interventional clinical trial, excluding observational\u002Fnatural history studies, at the start of the study or within the last 30 days before the start of the study.\n* Previous use of vitamin B3 (NAM), with abstinence required for at least 3 months before screening.\n* Pregnant women as determined by a positive high-sensitivity serum or urine pregnancy test (minimum sensitivity of 25 IU\u002FL or equivalent units of hCG) within 24 hours prior to screening, dosing, or completion of the study. Women of childbearing potential (WOCBP) will undergo a pregnancy test (serum or urine) 24 hours prior to screening, dosing, or completion of the study. Such participants must use a highly effective contraceptive method, such as combined hormonal contraceptives or intrauterine device (IUD), in accordance with the Clinical Trial Facilitation Group, throughout the entire study.\n* Breastfeeding women.\n* Patients undergoing treatment\u002Fsupplementation with vitamin E.\n* Patients receiving probiotics.\n* Patients on the waiting list for bariatric surgery in the next 12 months.\n* Patients undergoing treatment with drugs that may have an effect on the progression of liver disease.\n* Drugs for the treatment of T2DM with effects on NAFLD (GLP-1 analogs, thiazolidinediones such as pioglitazone) initiated within 6 months before the study start.\n* Drugs for the treatment of T2DM with effects on intestinal microbiota (metformin, α-GI inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors) initiated within 6 months before the study start.\n* Patients who do not sign the informed consent.\n* Patients with contraindications to the contrast agent to be used in imaging tests.","85 Years",{"count":302,"type":22},30,[267],"The objective of this clinical trial, a pilot study, is to assess the impact of nicotinamide (NAM) on individuals with hepatic fibrosis.\n\nThe main question it aims to answer is:\n\n\\- To determine if the treatment with NAM is able to arrest, or even reduce, the hepatic fibrosis.\n\nIn addition, we also want to study the effect of NAM on:\n\n* General parameters (weight, HOMA-IR, etc).\n* Adiposity distribution (liver and body).\n* Systemic inflammation.\n* Thermogenic capacity of adipose tissue.\n* Microbiota composition.\n\nResearchers will compare NAM to a placebo, to see if NAM can arrest or revert hepatic fibrosis and its associated effects.\n\nParticipants will take either NAM or placebo. The dosage will be 1.2g\u002Fm2 NAM per day, for one year.",[28,27,306,307,308,309],"Hepatic Fibrosis","NAFLD","Nicotinamide","Overweight and Obese Adults",[308,311,312],"Fatty liver","Nafld","2025-11-14",{"date":315,"type":40},"2025-11-18",{"date":317,"type":40},"2024-04-23",{"date":319,"type":22},"2028-12",{"name":321,"class":80},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",{"id":323,"slug":4,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":16,"sex":17,"minAge":328,"maxAge":4,"enrollmentInfo":329,"targetDuration":18,"studyType":23,"phases":4,"briefSummary":331,"conditions":332,"keywords":340,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":48},"100287699","NCT03025074","Blood Collection Biorepository for Liver Disease Research","Virology, Immunology and Mechanisms of Liver Disease in Patients With Hepatitis C and Other Liver Diseases","Inclusion Criteria:\n\n* This protocol is to establish a biobank of blood samples from individuals with or without liver diseases including viral hepatitis, liver cancer, NASH, and negative control samples.\n* Children and teenagers will be special populations considered in this protocol.\n\nExclusion Criteria:\n\n* Vulnerable populations such as adults unable to consent, infants, pregnant women or prisoners will not be considered for this research study.","7 Years",{"count":330,"type":22},1000,"The purpose of establishing a biorepository is to provide high quality specimens (serum, plasma, buffy coat and liver tissue) for future researchers who are studying the effects that fatty liver and viral diseases have on the liver.",[333,334,335,336,337,28,338,339],"Non-Alcoholic Steatohepatitis(NASH)","Hepatitis C","Hepatitis B","Fibrosis","Cirrhosis","Obesity, Childhood","Bariatric Surgery Candidate",[341,27,342,343,344],"Liver Disease","Hepatitis","HIV","Hepatology","2025-08-20",{"date":347,"type":40},"2025-08-27",{"date":349,"type":4},"2013-07",{"date":351,"type":22},"2099-12",{"name":353,"class":80},"State University of New York at Buffalo",{"id":355,"slug":4,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":357,"acronym":358,"eligibilityCriteria":359,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":181,"enrollmentInfo":360,"targetDuration":4,"studyType":59,"phases":362,"briefSummary":363,"conditions":364,"keywords":369,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":389},"100566936","NCT06661655","Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD\u002FMASH Patients","ACOUSTIQ","Inclusion Criteria:\n\n* Adult patient below 80 yo\n* Patients with MASLD\u002FMASH recruited in interventional trials requiring MRI PDFF +\u002F- MRE per interventional protocol, OR\n* Patients with MASLD\u002FMASH recruited in prospective cohorts requiring MRI PDFF +\u002F- MRE per interventional protocol, OR\n* Patients referred to MRI-PDFF or MRE.\n* Patients who consented in written to participate in the study\n* Patients with ongoing social security coverage\n\nExclusion Criteria:\n\n* Patient in their minority (less than 18 yo) or older than 80 yo,\n* Patient with active implants,\n* Patient presenting with a wound where the Hepatoscope exam shall be performed (abdominal right upper quadrant)\n* Patient with a history of decompensated cirrhosis,\n* Patient with a history of hepatocellular carcinoma,\n* Adult patient under tutorship, or unable to express informed consent,\n* Pregnant or breast-feeding\n* Person deprived from their liberty\n* Patient hospitalized without providing consent or in case of an emergency\n* Patient presenting with another know liver disease",{"count":361,"type":22},120,[61],"The objective of the study is to evaluate an ultraportable ultrasound device, Hepatoscope, for the non-invasive assessment of hepatic steatosis in patients with metabolic-dysfunction associated liver diseases (MASLD), by comparing its measurements with current diagnostic modalities, such as MRI-PDFF.",[365,28,366,64,367,368,307],"Metabolic Syndrome X","MASH - Metabolic Dysfunction-Associated Steatohepatitis","NASH (Non-Alcoholic Steatohepatitis)","Steatosis, Liver",[370,336,371,372,373,374,375,376,377,378],"Liver","Steatosis","Elastography","Ultrasound","Attenuation","Backscattering coefficient","Sound speed","MRI PDFF","Hepatoscope","2025-08-12",{"date":381,"type":40},"2025-08-15",{"date":383,"type":40},"2025-07-24",{"date":385,"type":22},"2026-09-01",{"name":387,"class":388},"E-Scopics","INDUSTRY",3,{"id":391,"slug":4,"hasResults":11,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":208,"enrollmentInfo":397,"targetDuration":4,"studyType":59,"phases":399,"briefSummary":400,"conditions":401,"keywords":408,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":48},"100598184","NCT07068191","Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly","Randomized Comparative Clinical Study of the Dietary Supplement \"Gepaktiv\" (International Name: Phenomenon) in Comparison With Ursodeoxycholic Acid (UDCA) and Ademetionine in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) and Hepatomegaly","HEPACT","Inclusion Criteria:\n\n* Age 18 to 65 years\n* Confirmed diagnosis of metabolic-associated fatty liver disease (MAFLD)\n* Hepatomegaly confirmed by ultrasound (≥3 cm craniocaudal liver enlargement)\n* ALT level between 90-150 U\u002FL\n* Steatosis ≥260 dB\u002Fm by FibroScan (CAP)\n* Fibrosis ≥11 kPa by transient elastography (FibroScan)\n* Ability to comply with study procedures\n* Signed informed consent\n\nExclusion Criteria:\n\n* Liver cirrhosis or hepatocellular carcinoma\n* Pregnancy or lactation\n* Known allergy to any of the study medications or supplement components\n* Gallstones or biliary obstruction\n* Shrunken liver on imaging\n* Hepatic cysts (simple liver cysts\u002Fbiliary cysts)\n* Liver nodules (focal liver lesions)",{"count":398,"type":22},90,[61],"This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver enlargement (hepatomegaly).\n\nKey points:\n\n* Participants will receive either Gepaktiv, UDCA, or Ademetionine for 15 days\n* Doctors will monitor liver health through blood tests and ultrasound scans\n* The study will check if Gepaktiv helps improve liver function as effectively as standard treatments.\n\nMain measurements:\n\n* Changes in liver enzyme levels (ALT, AST)\n* Reduction in liver size\n* Improvement in fat accumulation (steatosis) measured by FibroScan This research may provide evidence for a new natural option to support liver health.Data analysis will be done by an independent biostatistics",[402,403,404,405,28,406,239,407],"Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)","Hepatomegaly","Nonalcoholic Fatty Liver (NAFL)","Nonalcoholic Fatty Liver Disease (NAFLD)","Fatty Liver, Alcoholic","Fatty Liver Disease",[403,409,410,411,412,413,414,370,415,416,28],"Gepaktiv","Metabolic dysfunction-associated fatty liver disease (MAFLD)","metabolic dysfunction-associated steatotic liver disease (MASLD)","Nonalcoholic fatty liver disease (NAFLD)","liver diseases","Nonalcoholic fatty liver (NAFL)","Liver steatosis","Dietary supplements","2025-07-19",{"date":419,"type":40},"2025-07-23",{"date":421,"type":40},"2025-06-19",{"date":423,"type":22},"2025-08",{"name":425,"class":80},"Phenomen Pharma",{"id":427,"slug":4,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":64,"eligibilityCriteria":431,"healthyVolunteers":16,"sex":17,"minAge":87,"maxAge":181,"enrollmentInfo":432,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":434,"conditions":435,"keywords":439,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":445,"locationsCount":48},"100429529","NCT04873258","Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease","Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Volunteers on Clinical Trials Utilising Machine-learning and Bioimpedance Vector Analysis","Inclusion Criteria:\n\n1. Male or female volunteers aged ≥18 to ≤80 years at the date of signing the informed consent.\n2. Willingness and ability to provide written, personally signed, and dated informed consent, in accordance with the latest ICH Good Clinical Practice (GCP) Guidelines and applicable regulations.\n3. An understanding, ability and willingness to fully comply with project procedures and restrictions.\n\nFor PART B only:\n\n1\\. With a known history of MASLD as evidenced either of:\n\n1. GP diagnosis on HCF\n2. Documented Fibroscan or liver US demonstrating MASLD\n\nExclusion Criteria:\n\n1. Known alcoholic liver disease, history of cirrhosis of any other cause (metabolic, viral hepatitis or other)\n2. Any other significant previous liver pathology (liver malignancy, portal hypertension, infiltrative liver disease)\n3. Alcohol consumption \\>30 units per week\n4. An Implanted cardiac devices",{"count":433,"type":22},2000,"A generic screening study to establish structural and\u002For functional baselines of specific organs.",[436,28,64,437,438],"Healthy","MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","Obesity and Obesity-related Medical Conditions",[311,64],"2025-07-18",{"date":419,"type":40},{"date":443,"type":40},"2019-09-27",{"date":225,"type":22},{"name":446,"class":388},"Richmond Research Institute",{"id":448,"slug":4,"hasResults":11,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":11,"sex":17,"minAge":453,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":59,"phases":455,"briefSummary":457,"conditions":458,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":48},"100592153","NCT06989723","Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes","Evaluation of Pioglitazone and Empagliflozin Combination Therapy in Type 2 Diabetes Patients With Metabolic Dysfunction-Associated Fatty Liver Disease","Inclusion Criteria:\n\n1. Adults aged 20 years or older.\n2. Patients with inadequately controlled type 2 diabetes mellitus, defined as HbA1c between 7% and 10%, who are currently treated with either:\n\n   * Combination therapy of metformin and a sulfonylurea, or\n   * Combination therapy of metformin and a DPP-4 inhibitor, or\n   * Metformin monotherapy, or\n   * Triple therapy (including metformin) provided that sulfonylurea will be discontinued upon study enrollment.\n3. Evidence of hepatic steatosis within the past 3 months, confirmed by Fibroscan with a controlled attenuation parameter (CAP) ≥ 268 dB\u002Fm (consistent with S2 or greater \\[≥10% hepatocyte steatosis\\] according to the 2024 EASL-EASD-EASO guidelines).\n4. Presence of at least one of the following metabolic abnormalities:\n\n   * Waist circumference ≥90 cm for men or ≥85 cm for women.\n   * Blood pressure ≥130 mmHg systolic or ≥85 mmHg diastolic, or use of antihypertensive medication.\n   * Serum triglycerides ≥150 mg\u002FdL or current use of lipid-lowering agents.\n   * HDL-cholesterol ≤45 mg\u002FdL for men or ≤50 mg\u002FdL for women.\n   * HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) ≥2.5.\n   * Serum C-reactive protein (CRP) ≥2 mg\u002FL.\n5. No changes in anti-diabetic or metabolic medications within the past 3 months, unless the changes are deemed by the investigator not to affect study outcomes.\n\nExclusion Criteria:\n\n1. Patients receiving insulin therapy or diagnosed with type 1 diabetes mellitus.\n2. Use of the following medications within the past 3 months: GLP-1 receptor agonists, SGLT2 inhibitors, rosiglitazone (TZD), vitamin E, or ursodeoxycholic acid (UDCA).\n3. Presence of secondary causes of hepatic steatosis unrelated to metabolic dysfunction, such as hepatitis B, hepatitis C, or alcoholic fatty liver disease.\n4. Use of medications known to induce hepatic steatosis, including valproic acid, estrogen, tamoxifen, amiodarone, or chloroquine.\n5. Severe organ failure, defined as:\n\n   * Liver failure: AST or ALT \\> 5 times the upper normal limit (UNL), serum albumin \\\u003C 3.2 g\u002FdL, platelet count \\\u003C 60,000\u002FµL, or Child-Pugh-Turcotte stage B or C.\n   * Renal failure: Serum creatinine ≥ 2.0 mg\u002FdL, estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m² (CKD-EPI formula), or patients with end-stage renal disease or on dialysis.\n6. Presence of hepatocellular carcinoma, active malignancy, or metastatic cancer.\n7. History of or active bladder cancer.\n8. History of heart failure or current diagnosis of heart failure.\n9. Presence of terminal illnesses.\n10. History of gallstone disease, chronic pancreatitis, or acute pancreatitis.\n11. Underweight patients (body mass index \\[BMI\\] \\\u003C 18.5 kg\u002Fm²).\n12. Pregnant women or women planning to become pregnant.\n13. Known hypersensitivity to the active ingredients or excipients of the study medications.\n14. History of diabetic ketoacidosis.","20 Years",{"count":361,"type":22},[456],"PHASE4","This exploratory study will assess the efficacy of combined pioglitazone and empagliflozin therapy in improving hepatic and metabolic outcomes in patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease (MAFLD). Although each agent has shown beneficial effects individually, evidence on their combined impact on liver health is scarce. This study seeks to determine whether the combination therapy yields additive improvements in hepatic steatosis, inflammation, and fibrosis, potentially offering a new therapeutic strategy for diabetic patients with fatty liver disease.",[459,28],"Type 2 Diabetes","2025-05-22",{"date":462,"type":40},"2025-05-25",{"date":464,"type":40},"2025-01-01",{"date":466,"type":22},"2027-06-30",{"name":468,"class":80},"Seoul National University Bundang Hospital",{"id":470,"slug":4,"hasResults":11,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":181,"enrollmentInfo":475,"targetDuration":4,"studyType":59,"phases":477,"briefSummary":478,"conditions":479,"keywords":480,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":48},"100514918","NCT05984745","Effect of CoQ10 on the Outcome of MAFLD Patients","Effect of Coenzyme Q10 on the Outcome of Metabolic Dysfunction-Associated Fatty Liver Disease Patients","Inclusion Criteria:\n\nAll study subjects and prior to consenting to the ICF, laboratory and imaging work-up will be evaluated for the presence of three out of five criteria for metabolic dysregulation in the context of metabolic -dysfunction associated fatty liver disease (MAFLD):\n\n1. Waist circumference (WC) ≥ 102\u002F88 cm for men and women respectively.\n2. HDL cholesterol \\\u003C40 mg\u002Fdl in men and \\\u003C50 mg\u002Fdl in women or on specific drug therapy.\n3. Plasma Triglycerides ≥ 150 mg\u002Fdl or on specific drug therapy.\n4. Blood pressure ≥130 and\u002For ≥ 85 or on specific anti-hypertensive therapy.\n5. Fasting blood glucose ≥ 100 mg\u002Fdl or on specific anti hyperglycemic therapy\n\n   * Patients who agree to sign an informed consent\n   * Adult patients \\>18 years old.\n   * Males and females\n   * Willing to comply with procedures and follow up\n   * Elevated serum transaminases (1-4 times the ULN)\n   * Imaging evidence of fatty liver:\n\npelviabdominal ultrasound and Fibro- CAP study\n\nExclusion Criteria:\n\n* Pregnancy or lactating\n* Physical or mental abnormalities\n* HCV infection\n* HBV infection\n* Anaemia\n* Thrombocytopenia\n* Haematological malignancies\n* Ongoing alcoholism (Male: \\>30g\u002Fday, Female: \\>20g\u002Fday)\n* Patients with renal failure\n* Autoimmune hepatitis\n* Celiac disease\n* Wilson's disease\n* Hemochromatosis\n* Drugs: Tamoxifen, Valproic acid, Amiodarone, Methotrexate, Steroids, Anticoagulants, All anti-oxidative stress agents, Cos, IUD\n* Chronic use of systematically immunosuppressive agent or drugs that can affect liver profile.\n* Hypo\u002FHyper-thyroidism\n* Bypass surgeries\n* TPN (Total Parenteral Nutrition)",{"count":476,"type":22},60,[267],"So far there has been no universal treatment for MAFLD since it has a complex etiology that involves ethnic, genetic, metabolic and environmental factors. However, therapeutic life changes including: diet, weight loss, and physical activity remain the cornerstone of treatment and is recommended by both American and European associations.\n\nInflammatory biomarkers, such as tumor necrosis factor-alpha, and adipokines play key roles in the pathogenesis of MAFLD, hence, the anti-inflammatory and antioxidant effects of coenzyme Q10 especially at high doses that have not been tested are hypothesized to have a beneficial role in improving the systemic inflammation and biochemical variables.\n\nThis study is conducted to test this hypothesis",[28,307],[481,415,482,28,483,484,485,486,341],"Coenzyme Q10","TNF alpha","Inflammation","MAFLD","CoQ10","Ubiquinone","2025-03-22",{"date":489,"type":40},"2025-03-26",{"date":491,"type":40},"2023-10-31",{"date":493,"type":22},"2025-12",{"name":495,"class":80},"Ain Shams University",{"id":497,"slug":4,"hasResults":11,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":11,"sex":17,"minAge":502,"maxAge":181,"enrollmentInfo":503,"targetDuration":4,"studyType":59,"phases":505,"briefSummary":506,"conditions":507,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":4},"100583214","NCT06873412","Effects of Compound Probiotics-Polygonatum Sibiricum on Liver Health and Metabolism in Middle-aged and Elderly People","The Regulatory Effect of Probiotics-Polygonatum Sibiricum on Liver Health and Metabolic Disorders in Middle-Aged and Elderly People: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study","Inclusion Criteria:\n\n1\\. The age of the subjects is 40-80 years old; 2. The subject meets one of the following metabolic disease components: ① abdominal B - ultrasound shows fatty liver or fat infiltration; ② arterial blood pressure is higher than 130\u002F85mmHg, or the subject is on antihypertensive treatment; ③ prediabetes or type 2 diabetes, with fasting blood glucose above 6.1mmol\u002FL; ④ overweight or obesity, with BMI of 24.0kg\u002Fm² or more, or male waist circumference of 90cm or more, female waist circumference of 85cm or more, or excessive body fat content and percentage.\n\n\\-\n\nExclusion Criteria:\n\n1. People who are allergic to any of the pharmaceutical ingredients used in this study; A history of alcohol abuse (drinking more than 14 units of alcohol per week :1 unit = 285mL for beer, 25mL for spirits, 100mL for wine);\n2. Patients who received probiotics within 1 month before taking the experimental drug;\n3. Recent history of gastrointestinal bleeding, obstruction, perforation, tumor and other serious organic diseases;\n4. Aminotransferase index \\> 3 times the normal value;\n5. Kidney disease (creatinine index higher than normal);\n6. Patients with serious psychological and mental diseases, resulting in the inability to express themselves normally;\n7. Patients with infectious liver diseases, such as hepatitis B and C;\n8. The female subject is breastfeeding or has a positive pregnancy test result during the screening period or during the test -","40 Years",{"count":504,"type":22},84,[61],"The purpose of this study was to evaluate the regulatory effects of Huangqian-biobacteria compound preparation on liver health and related metabolic disorders in middle-aged and elderly people, observe its effects on liver function indexes, basal metabolic rate, markers of oxidative stress, inflammatory factors and intestinal microecology, and evaluate the incidence of adverse reactions in subjects during the 3-month intervention period.",[28],"2025-03-06",{"date":510,"type":40},"2025-03-12",{"date":512,"type":22},"2025-03-10",{"date":514,"type":22},"2026-12-01",{"name":516,"class":388},"Wecare Probiotics Co., Ltd.",{"id":518,"slug":4,"hasResults":11,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":208,"enrollmentInfo":523,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":525,"conditions":526,"keywords":528,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":48},"100545760","NCT06386094","Cardiac Dysfunction in Patients with Fatty Liver Disease","Cirrhotic Cardiomyopathy and Cardiac Dysfunction in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease","Inclusion Criteria:\n\n* Age range of 18-65 years\n* metabolic dysfunction associated steatotic liver disease as diagnosed either by histology or clinical, laboratory, non invasive tests, USG findings and vibration controlled transient elastography (VCTE).\n\nExclusion Criteria:\n\n* Age \\>65 years\n* Chronic renal disease\n* Pregnancy and peripartum cardiomyopathy\n* Hypertension\n* Valvular heart disease\n* Sick sinus syndrome\u002F Pacemaker\n* Cardiac rhythm disorder\n* Hypothyroidism\n* Hyperthyroidism\n* Portal vein thrombosis\n* Transjugular intrahepatic porto systemic shunt (TIPS) insertion\n* Hepatocellular carcinoma\n* Anemia Hb \\\u003C 8gm\u002Fdl in females, and \\\u003C 9 gm\u002Fdl in males at the time of assessment",{"count":524,"type":22},150,"Cirrhotic cardiomyopathy is seen as a blunted contractile responsiveness to stress, and\u002For altered diastolic relaxation with electrophysiological abnormalities, in absence of known cardiac disease. Left ventricular diastolic dysfunction (LVDD) is associated with risk of hepatorenal syndrome (HRS) , septic shock. , heart failure in the perioperative period following liver transplantation, and after trans-jugular intrahepatic portosystemic shunt (TIPS) insertion . The echocardiographic E\u002Fe' ratio is a predictor of survival in LVDD, with multiple studies, including prospective data from our Centre. The inability of the heart to cope with stress or sepsis induced circulatory failure is a key concept of the increased mortality risk due to LVDD. In view of the metabolic syndrome and diabetes epidemic and an increasing number of patients being diagnosed with non-alcoholic fatty liver disease, there is increased risk of developing cardiac dysfunction due to multiple comorbidities including coronary artery disease, hypertensive heart disease, cirrhotic cardiomyopathy, which are contributors to overall cardiovascular risk of mortality.",[307,527,28,437],"Cardiac Disease",[64,529,530,531],"Cirrhotic Cardiomyopathy","Heart failure in Cirrhosis","Coronary Artery Disease","2025-01-27",{"date":534,"type":40},"2025-01-29",{"date":536,"type":40},"2023-07-15",{"date":538,"type":22},"2027-11-15",{"name":540,"class":80},"Post Graduate Institute of Medical Education and Research, Chandigarh",{"id":542,"slug":4,"hasResults":11,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":262,"enrollmentInfo":546,"targetDuration":548,"studyType":23,"phases":4,"briefSummary":549,"conditions":550,"keywords":552,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":4},"100564401","NCT06628700","Burden Fatty Liver Among Acute Ischemic Cerebral Stroke Patients","Inclusion Criteria:\n\n* Newly diagnosed ischemic cerebral stroke exceeding of window phase without obvious risk factors.\n* patients above 18 years.\n* patients below 60 years.\n\nExclusion Criteria:\n\n* patients have obvious risk factors including: smoking, DM , Hypertension ,renal patients , cardiovascular diseases (AF , valvular disease ,reduced systolic function ,chronic HCV ,HBV).\n* patients below 18 years.\n* patients above 60 years.\n* patients refused to contribute to this study.",{"count":547,"type":22},97,"20 Days","1. Assess frequency of hepatic steatosis among patients in patients with Ischemic stroke without previous risk factors\n2. Assess outcomes morbidity and mortality ischemic stroke in correlation with hepatic steatosis .",[28,551],"Acute Ischemic Cerebral Stroke",[311,553,164],"Acute ischemic cerebral stroke","2024-10-03",{"date":556,"type":40},"2024-10-08",{"date":558,"type":22},"2024-10-10",{"date":560,"type":22},"2025-11-10",{"name":562,"class":80},"Assiut University",{"id":564,"slug":4,"hasResults":11,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":208,"enrollmentInfo":569,"targetDuration":4,"studyType":59,"phases":570,"briefSummary":571,"conditions":572,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":579,"locationsCount":48},"100531726","NCT06203548","Monitoring Changes in Hepatic Steatosis Using Continuous Controlled Attenuation Parameter","Monitoring Changes in Hepatic Steatosis During a Lifestyle Intervention Programme in Patients With Non-alcoholic Fatty Liver Disease Using the Novel Continuous Controlled Attenuation Parameter Versus MRI Proton Density Fat Fraction","Inclusion Criteria:\n\n* Intrahepatic triglyceride content by MRI-PDFF ≥5%\n* At least one metabolic risk factor out of (1) body-mass index ≥23 kg\u002Fm2, (2) waist circumference ≥90 cm in men and ≥80 cm in women, (3) fasting plasma glucose ≥5.6 mmol\u002FL, 2-hour post-load glucose ≥7.8 mmol\u002FL, haemoglobin A1c (HbA1c) ≥5.7%, known diabetes or on treatment for type 2 diabetes, (4) blood pressure ≥130\u002F85 mmHg or on treatment for hypertension, (5) plasma triglycerides ≥1.7 mmol\u002FL or on treatment for dyslipidaemia, and (6) plasma high-density lipoprotein-cholesterol ≤1.0 mmol\u002FL in men and ≤1.3 mmol\u002FL in women or on treatment for dyslipidaemia\n* Provide informed written consent\n\nExclusion Criteria:\n\n* Positive hepatitis B surface antigen or anti-hepatitis C virus antibody, or history or evidence of other liver diseases\n* Alcohol consumption \\>30 g per day in men or \\>20 g per day in women\n* Liver decompensation, as evidenced by total bilirubin \\>50 µmol\u002FL (except in patients with documented Gilbert's syndrome), platelet count \\\u003C100 x 109\u002FL, prothrombin time \\>1.3 times the upper limit of normal, albumin \\\u003C35 g\u002FL, or history or presence of ascites, varices or hepatic encephalopathy\n* Contraindications to MRI examination such as claustrophobia or the presence of metallic implants\n* History or presence of hepatocellular carcinoma\n* History of other malignancies, unless in complete remission for more than 5 years\n* History of liver transplantation or liver resection\n* Significant co-morbidities that will likely limit a patient's participation in lifestyle intervention or attendance of study follow-ups",{"count":524,"type":22},[61],"Background: Non-alcoholic fatty liver disease (NAFLD) affects 30% of the Asian adult population and is emerging as one of the important leading causes of liver cancer and cirrhosis. Although a number of biomarkersmany have been developed for the assessment of liver fat and fibrosis, most existing studies were cross-sectional in nature. The role of these biomarkers for monitoring and response assessment remains elusive. At present, magnetic resonance imaging proton density fat fraction (MRI-PDFF) is considered the gold standard to in quantifying liver fat. The MRI-PDFF response, defined as a ≥30% relative reduction in liver fat fraction, has been shown to correlate with improved hepatic inflammation and fibrosis. However, MRI is limited by cost and availability. The cContinuous controlled attenuation parameter (CAPc) measurement by vibration controlled transient elastography is a new technology to quantify liver fat. It is a point-of-care test and has the potential to replace the MRI-PDFF as a monitoring and response biomarker in routine practice.\n\nStudy plan: This prospective cohort study will include 150 patients with NAFLD who will join a 6-month lifestyle modification programme involving dietary intervention and physical training. This will create a cohort of varying degrees of liver fat reduction. Using MRI-PDFF as the reference standard, we will evaluate the accuracy of a changes in CAPc in reflecting the MRI-PDFF response and remission of NAFLD, with all non-invasive tests performed at screening and Month 6. In addition, we will test the hypothesis that the the change in CAPc is superior to the change of in other steatosis tests results (including the original CAP, abdominal ultrasonography and steatosis scores of fatty liver index, hepatic steatosis index, NAFLD liver fat score and NAFLD ridge score) in predicting the MRI-PDFF response. The area under the receiver-operating characteristics curve of the CAPc response in predicting the MRI-PDFF response will be compared with that of the other steatosis tests using the DeLong test.",[28],"2024-08-08",{"date":575,"type":40},"2024-08-09",{"date":577,"type":40},"2024-02-01",{"date":198,"type":22},{"name":580,"class":80},"Chinese University of Hong Kong",{"id":582,"slug":4,"hasResults":11,"nctId":583,"briefTitle":584,"officialTitle":584,"acronym":4,"eligibilityCriteria":585,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":586,"targetDuration":588,"studyType":23,"phases":4,"briefSummary":589,"conditions":590,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":4},"100549390","NCT06433388","Perirenal Fats of Chronic Kidney Disease in Patients With Fatty Liver Disease.","Inclusion Criteria:\n\n* Age more than 18 years old regardless of gender\n\nExclusion Criteria:\n\n* Other causes of chronic liver diseases (HCV, HBV...).\n* End stage renal diseases (GFR\\\u003C15 ml\u002Fmin).\n* A history of significant alcohol intake (\\>20 g\u002Fday in females and 30 g\u002Fday in males).\n* Those using medications that can cause fatty liver.\n* Pregnant patients.",{"count":587,"type":22},70,"1 Year","Exploring the association of perirenal fat thickness assessed by MRI in CKD patients with FLD.",[591,28],"Chronic Kidney Diseases","2024-07-21",{"date":594,"type":40},"2024-07-23",{"date":596,"type":22},"2024-08",{"date":598,"type":22},"2025-09",{"name":562,"class":80},{"id":601,"slug":4,"hasResults":11,"nctId":602,"briefTitle":603,"officialTitle":603,"acronym":4,"eligibilityCriteria":604,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":605,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":607,"conditions":608,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":615,"locationsCount":4},"100551198","NCT06456970","Frequency of Metabolic Dysfunction Associated Fatty Liver Disease in Patients With Acute Coronary Syndromes","Inclusion Criteria:\n\nAny Patient above the age of 18 years old presented with acute coronary syndromes {myocardial infarction (MI), non-ST elevation myocardial infarction (NSTEMI), unstable angina} underwent coronary angiography within admission.\n\nExclusion Criteria:\n\n1. Patients refused to participate.\n2. Patients with history of alcohol or drug abuse.\n3. Patients have hepatitis C or hepatitis B infection.\n4. Patients have primary or secondary hepatic malignancies\n5. Pregnant women.",{"count":606,"type":22},140,"Aim of the research is to assess frequency of MAFLD among patients with acute coronary syndromes (ACS).",[28],"2024-06-12",{"date":611,"type":40},"2024-06-13",{"date":613,"type":22},"2024-07-01",{"date":98,"type":22},{"name":562,"class":80},{"id":617,"slug":4,"hasResults":11,"nctId":618,"briefTitle":619,"officialTitle":620,"acronym":621,"eligibilityCriteria":622,"healthyVolunteers":11,"sex":623,"minAge":87,"maxAge":624,"enrollmentInfo":625,"targetDuration":4,"studyType":59,"phases":627,"briefSummary":628,"conditions":629,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":639,"locationsCount":48},"100351116","NCT03851627","Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight\u002FObese Men With T2DM or Prediabetes and Hypogonadism","52 Week RCT to Investigate the Effect of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Obese\u002FOverweight Men With T2DM\u002FPrediabetes and Hypogonadism and Subsequent 108 Week Open Label Phase to Investigate Effects on Cardiometabolic Parameters","Test2Func","Inclusion Criteria:\n\n* prediabetes\u002FT2DM\n* male sex\n* HbA1c \\>=5.7% -9.0% or fasting glucose \\>=100mg\u002Fdl or postprandial glucose\\>= 140mg\u002Fdl\n* Age \\>=18 -75 years\n* BMI\\>=25kg\u002Fm²\n* Hypogonadism assessed by laboratory testing (testosterone \\\u003C 4,04ng\u002Fml (=14nmol\u002Fl) Metformin 8 weeks stable dose, SGLT2 inhibitors 3 months stable dose, DPP4 inhibitors 3 months stable dose, GLP1 RA 3 months stable dose and long acting insulin (basal insulin) 8 weeks stable dose\n* able and willing to not change diet and physical activity during enrollment in study\n* consent and able to give informed consent.\n\nExclusion Criteria:\n\n* Current testosterone treatment or testosterone replacement within the last 12 month\n* Serum creatinine\\>1,5mg\u002Fdl\n* Liver enzymes above 3 fold normal range\n* PSA\\>4.0μg\u002Fl\n* Hematocrit\\>50%\n* Known intolerance to testosterone undecanoate or any of its ingredients\n* Myocardial infarction within the last 12month\n* Stroke within the last 12 month\n* Untreated congestive heart disease\n* malignancy within the last 5 years before randomization\n* Prostate cancer or any suspicion thereof\n* Breast cancer\n* Liver tumor\u002Fcancer\n* Epilepsy\n* Migraine\n* Presence of any absolute or relative contraindication for the conduct of an MRI investigation, such as cardiac pacemakers, ferromagnetic haemostatic clips in the central nervous system, metallic splinters in the eye, ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators, cochlear implants, insulin pumps and nerve stimulators, prosthetic heart valves etc.\n* patients on antidiabetic medication like Sulfonylurea or Glitazones.\n* Any other clinical condition that would jeopardize patients safety while participating in this clinical trial\n* Known autoimmune disease or chronic inflammatory condition\n* Other liver disease including chronic viral hepatitis (B or C), alcohol abuse, hemochromatosis, alpha-1 antitrypsin deficiency, autoimmune hepatitis, Wilson's disease, primary sclerosing cholangitis or primary biliary cirrhosis, or liver cirrhosis of any etiology\n* Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake\n* History of bariatric surgery\n* Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight\n* Subjects receiving antihypertensive medication and\u002For thyroid hormones, the dose(s) of which have not been stable for at least 6 weeks prior to baseline\n* Uncontrolled\u002F untreated hypertension\n* Current treatment with systemic steroids at time of informed consent. (Treatment with local and inhaled steroids is allowed)\n* Donation of blood (\\> 400 mL) during the previous 3 months prior to the screening visit or during the duration of the study\n* Participation in another trial with an investigational drug within 30 days prior to informed consent.\n* Pharmacist, study coordinator, other staff thereof, directly involved in the conduct of the protocol.\n* contraindication for intramuscular injection (e.g patient receiving anticoagulants on a regular basis such as NOAKs or VKAs, or DAPT).\n* COPD Gold IV or recurrent acute or allergic asthma (for MPI)\n* Contraindications for cardiac stress test as acute myocardial infarction, instable angina, severe hypertension, myocarditis, life threatening rhythmic disorders without physical activity.","MALE","75 Years",{"count":626,"type":22},32,[456],"The epidemics of obesity, MeTSy, T2DM and CVD are increasing worldwide. Non-alcoholic fatty liver disease (NAFLD) is becoming recognized as a condition possibly involved in the pathogenesis of these diseases. The prevailing hypothesis for NAFLD pathogenesis is the 'two-hit' model, with insulin resistance and hyperinsulinemia playing essential roles, which have a plethora of effects on hepatic lipid metabolism and can lead to accumulation of triglycerides in hepatocytes. Accepted treatment for NAFLD is lifestyle modifications. Sex hormones might be relevant in T2DM development and treatment. Low testosterone (T) has deteriorating effects on glucose levels, and aggravates in obesity as aromatization of T is enhanced. T deficiency is related to increases of visceral fat accumulation and associated with development of NAFLD. T replacement might be a successful way in hypogonadism to treat obesity and counteract progression of MEtSy,T2DM or CVD driven by visceral fat accumulation or NAFLD.\n\nPrimary Objective To investigate the effects on hepatic lipid content reduction of a therapy with Testosterone undecanoate 1000mg compared to placebo given for 52 weeks in patients with type 2 diabetes mellitus and hypogonadism.",[28,630,631,632],"Overweight\u002FObesity","Prediabetes\u002FType2 Diabetes Mellitus","Hypogonadism, Male","2024-03-12",{"date":635,"type":40},"2024-03-13",{"date":637,"type":40},"2022-01-25",{"date":319,"type":22},{"name":640,"class":80},"Alexandra Kautzky-Willer",""]